Patents by Inventor Joseph D. Panarese
Joseph D. Panarese has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11976084Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 22, 2021Date of Patent: May 7, 2024Assignee: Enanta Pharmaceuticals, Inc.Inventors: Guoqiang Wang, Ruichao Shen, Jun Ma, Yong He, Xuechao Xing, Hui Cao, Xuri Gao, Xiaowen Peng, Joseph D. Panarese, Yat Sun Or
-
Publication number: 20240140922Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the cellular entry of hepatitis B virus (HBV) and/or hepatitis D virus (HDV) or interfere with the function of the life cycle of HBV and/or HDV and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV and/or HDV infection. The invention also relates to methods of treating an HBV and/or HDV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: August 22, 2023Publication date: May 2, 2024Inventors: Samuel Bartlett, Joseph D. Panarese, Sourav Ghorai, Nathaniel Thomas Kenton, Sean Rafferty, Jonathan Thielman, Peilin Xu, Bin Wang, William Cassels, Scott Mitchell, Yat Sun Or
-
Patent number: 11952389Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: May 3, 2022Date of Patent: April 9, 2024Assignee: Enanta Pharmaceuticals, Inc.Inventors: Brian C. Shook, In Jong Kim, Thomas P. Blaisdell, Jianming Yu, Joseph D. Panarese, Yat Sun Or
-
Patent number: 11858945Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 9, 2022Date of Patent: January 2, 2024Assignee: Enanta Pharmaceuticals, Inc.Inventors: Joseph D. Panarese, Samuel Bartlett, Guoqiang Wang, Yat Sun Or
-
Publication number: 20230416268Abstract: The present invention provides compounds of Formula (I), pharmaceutical compositions comprising these compounds and methods of using these compounds for treating a metabolic disease or liver condition. The present invention relates generally to compounds and pharmaceutical compositions useful as 17?-HSD13 inhibitors. Specifically, the present invention relates to compounds useful as inhibitors of 17?-HSD13 and methods for their preparation and use.Type: ApplicationFiled: April 26, 2023Publication date: December 28, 2023Inventors: Yat Sun Or, Joseph D. Panarese, Guoqiang Wang, Jing He, Jiang Long, Jun Ma, Bin Wang, Sourav Ghorai
-
Patent number: 11802125Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: March 15, 2021Date of Patent: October 31, 2023Inventors: Joseph D. Panarese, Dexter Davis, Nathaniel Thomas Kenton, Samuel Bartlett, Yat Sun Or
-
Publication number: 20230174542Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 6, 2022Publication date: June 8, 2023Inventors: Joseph D. Panarese, Sean Rafferty, Jonathan Thielman, Nathaniel T. Kenton, Samuel Bartlett, Yat Sun Or
-
Publication number: 20230174531Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 6, 2022Publication date: June 8, 2023Inventors: Joseph D. Panarese, Samuel Bartlett, Yat Sun Or
-
Publication number: 20230159545Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 9, 2022Publication date: May 25, 2023Inventors: Joseph D. Panarese, Samuel Bartlett, Guoqiang Wang, Yat Sun Or
-
Publication number: 20230122228Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 14, 2022Publication date: April 20, 2023Inventors: Ruichao Shen, Yong He, Xuechao Xing, Matthew C. Rhodes, Joseph D. Panarese, Samuel Bartlett, Wei Li, Hui Cao, Jiajun Zhang, Xiaowen Peng, Guoqiang Wang, Yat Sun Or
-
Publication number: 20230103494Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 22, 2021Publication date: April 6, 2023Inventors: Guoqiang Wang, Ruichao Shen, Yong He, Jun Ma, Xuechao Xing, Hui Cao, Xuri Gao, Xiaowen Peng, Jiang Long, Wei Li, Jiajun Zhang, Joseph D. Panarese, Nathaniel Thomas Kenton, Samuel Bartlett, Yat Sun Or
-
Publication number: 20230087410Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: May 3, 2022Publication date: March 23, 2023Inventors: Brian C. Shook, In Jong Kim, Thomas P. Blaisdell, Jianming Yu, Joseph D. Panarese, Yat Sun Or
-
Publication number: 20220402926Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 13, 2022Publication date: December 22, 2022Inventors: Jiajun Zhang, Xiaowen Peng, Byung-Chul Suh, Jorden Kass, Xuri Gao, Hui Cao, Wei Li, Joseph D. Panarese, Guoqiang Wang, Yat Sun Or
-
Patent number: 11384090Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 20, 2021Date of Patent: July 12, 2022Assignee: Enanta Pharmaceuticals, Inc.Inventors: Guoqiang Wang, Ruichao Shen, Yong He, Xuri Gao, Jun Ma, Xuechao Xing, Hui Cao, Joseph D. Panarese, Yat Sun Or
-
Patent number: 11358953Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 9, 2021Date of Patent: June 14, 2022Assignee: Enanta Pharmaceuticals, Inc.Inventors: Joseph D. Panarese, Dexter Davis, Nathaniel Thomas Kenton, Samuel Bartlett, Sean M. Rafferty, Yat Sun Or
-
Patent number: 11352363Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 20, 2021Date of Patent: June 7, 2022Assignee: Enanta Pharmaceuticals, Inc.Inventors: Guoqiang Wang, Xuri Gao, Ruichao Shen, Yong He, Jiajun Zhang, Joseph D. Panarese, Hui Cao, Xuechao Xing, Yat Sun Or
-
Publication number: 20220162231Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: November 22, 2021Publication date: May 26, 2022Inventors: Guoqiang Wang, Ruichao Shen, Jun Ma, Yong He, Xuechao Xing, Hui Cao, Xuri Gao, Xiaowen Peng, Joseph D. Panarese, Yat Sun Or
-
Publication number: 20220162216Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 20, 2021Publication date: May 26, 2022Inventors: Guoqiang Wang, Ruichao Shen, Yong He, Xuri Gao, Jun Ma, Xuechao Xing, Hui Cao, Joseph D. Panarese, Yat Sun Or
-
Publication number: 20220162217Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: September 20, 2021Publication date: May 26, 2022Inventors: Guoqiang Wang, Xuri Gao, Ruichao Shen, Yong He, Jiajun Zhang, Joseph D. Panarese, Hui Cao, Xuechao Xing, Yat Sun Or
-
Patent number: 11319325Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 20, 2021Date of Patent: May 3, 2022Assignee: Enanta Pharmaceuticals, Inc.Inventors: Jiajun Zhang, Xiaowen Peng, Joseph D. Panarese, Guoqiang Wang, Yat Sun Or